Ablative free thyroxine to thyroglobulin ratio as a predictor of differentiated thyroid cancer recurrence

Journal of Otolaryngology - Head and Neck Surgery

Volumn 38, Issue 5, 2009, Pages 552-558

  Aron, Margaret ^a   Cote, Valerie ^b   Tamilia, Michael ^b   Hier, Michael ^b   Black, Martin J ^b   Zhang, Xun ^c   Payne, Richard J ^b,d  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d Montreal Children's Hospital Research Institute ^*  (Canada)

Author keywords

Follow up; Predictor; Recurrence; Thyroglobulin; Thyroid carcinoma; Thyroxine

Indexed keywords

THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROXINE;

ABLATION FREE THYROXINE TO THYROGLOBULIN RATIO; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TUMOR DIFFERENTIATION;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROXINE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70349508930     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2009.080255     Document Type: Article

References (18)

1. Duren M, Siperstein A, Shen W, et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 1999;126:13-19 (Pubitemid 29340686)
2. Oyen W, Verhagen C, Saris E, et al. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. J Nucl Med 2000;41:643-646 (Pubitemid 30207740)
3. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88: 3668-3673 (Pubitemid 37034512)
4. Menendez Torre E, Lopez Carballo MT, Rodríguez Erdozain RM, et al. Prognostic value of thyroglobulin serum levels and 131I whole-body scan after initial treatment of low-risk differentiated thyroid cancer. Thyroid 2004;14:301-306 (Pubitemid 38569280)
5. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45: 988-994 (Pubitemid 47611686)
6. Ronga G, Filesi M, Ventroni G, et al. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448-1452 (Pubitemid 29515606)
7. Grünwald F, Menzel C, Fimmers R, et al. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med 1996;37:1962-1964 (Pubitemid 26428362)
8. Hall FT, Beasley NJ, Eski SJ, et al. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 2003;113:77-81.
9. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90: 1440-1445
10. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-1441 (Pubitemid 36623351)
11. Sisson JC, Carey JE. Thyroid carcinoma with high levels of function: treatment with (131)I. J Nucl Med 2001;42:975-983 (Pubitemid 32537448)
12. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428 (Pubitemid 24345593)
13. Canadian Cancer Society. Canadian cancer statistics 2007. Available at: http://www.cancer.ca (accessed August 1, 2007).
14. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-112 (Pubitemid 38312801)
15. Passler C, Scheuba C, Prager G, et al. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocr Relat Cancer 2004;11:131-139 (Pubitemid 38419728)
16. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996;3:534-538 (Pubitemid 126729002)
17. Sherman SI. Overview of the management of differentiated thyroid cancer. Available at: www.uptodate.com (accessed April 2007).
18. Paul SJ, Sisson JC. Thyrotoxicosis caused by thyroid cancer. Endocrinol Metab Clin North Am 1990;19:593-612.